It will only sell when the consumers will have heard about it and ask the docs for it. But the catch 22 is that the docs have to be familiar with it to feel comfortable prescribing it. Give it time, buy now and wait for advertisements.
but there is also a drawback in AFREZZA BEING A CONSUMER PRODUCT, it still relies on doctors prescribing the drug to patients, so you have to give enough time for the docs to familiarize themselves with the drug. You can't massively launch Afrezza with PR and Advertisements and drive millions of diabetics to the doctors when the doctors aren't familiar with the drug. NO doc is ever goiing to prescribe a drug that they have no knowledge about; their license is on the line. Thus, you have to give it time for doctor's education and advertisement to happen.
Remember, Afrezza is not a cure or the ONLY diabetic treatment in the market. Thus, no doc is ever going to prescribe it, unless they know about it. It's not a cure or ONLY option drug, that is forced upon patients with the disease.
management compares afrezza to iphone; they are correct. If this picks up the market shares of 450 million diabetics world wide; every diabetics will want to inhale insulin because no psychopath will want needles. AFREZZA IS A CONSUMER PRODUCT, NOT a doctor's product. Doctors don't care if they give injection or inhaltion but the patients will care if their bellies or arms are getting stuck with needles. Thus, you have to wait for advertisement to decide how Afrezza does in the market.
Mnkd has a great diabetic partner, SNY.
Share price is ridiculously low, even a Buyout is over current market cap
They started a slow launch, just introducing AFrezza to a group of docs
when they Advertise, this will move like gangsbusters
They had to do a controlled launch because 1 production line could support the demand anyways.
Lines 2-3 increased production in preparation for demand increase
Here's a catch.....wait for it (even if Afrezza turns out to be a flop which i doubt because I have seen first hand on how it works, you will still have all they hypes with advertisements, plenty of time to get out for profits).
But if Afrezza is a success, in short term, the gain is 4-5 folds, long term is 20-100 folds
100 mill shares short coverage will have to buy; $1 is minimum, someone will buy technoshphere for at least a buck.
Thus, very little or zero risk here and huge upside.
it may not be foul play, if it was agreed upon by mnkd and sny
if you remember the partnership agreement, huge portion of that agreement was not disclosed to the public. Who knows what they were not telling us.
there is no lawsuit if it was agreed upon, as part of the partnership agreement. They informed investors that it would be "controlled launch"
there is no motive for an 89 yo billionaire who already owns 150 mil shares wanting to own 250 mil more shares. Burry himself with cash in his last decade of life doesn't make sense. Sharing the wealth and carrying legacy is more important at this stage.
I don't think Mann wants to take the company private. But I think in order for SNY to buyout Afrezza, they had to see with their own eyes how patients and docs are perceiving afrezza. If a set of 300 docs prescribe 200 scripts/wk without anyone knowing about it, except for mnkd and SNY execs, then buying out Afrezza would be easier without any competitive bids.
Mann could sell it for more if he chose to advertise himself; not sure why he gave that role to SNY, unless he had his love for SNY and wants sny to have it.
It doesn't make any sense for a guy at his age who already owns 150 mil shares wanting to own 250 mil more shares? What is gonna do with all that money? He would rather share the wealth and claim his legacy; instead of burying himself with greed. C'mon have some common sense.
Imagine the scenario in which SNY has been selling Afrezza ONLY to 300 docs and these docs write about 200 scripts/wk. That is 2 scripts/doc/wk; imagine when the floodgate of 225,000 docs will have been educated about Afrezza! And they will write about 225,000-500,000 scripts each week. SNY could acquire Afrezza for a fraction of the price. What a game they played on investors and shorts!!!!!
very plausible, how is it that the CEO has no clue as to what is going on with the company. Unless they gave up because it is sold already. Yes, he cancelled his shares sell plan, perhaps SNY/Al Mann finally came to a conclusion on the price.
I am long because my diabetic friend is using Afrezza and she loves it. That is the only thing I can base on; I have nothing else going for me.
Shorts brought it down to the 3's to cover and as soon as it hit 4, it was manipulated back down to cover again. They are shaking the trees really vigourously now. Any longs who can withstand this either lose it all or become very rich. This is the last ditch effort from the shorts before the floodgate of Afrezza PR/advertisement and Line 2-3 fully opened to accommodate the demand.
Too many investors on mnkd, any news, even Alfred Mann burping, will rally. Shorts are stuck while Afrezza launch is slow and steady, ready to release the floodgate of 1/4 million subscribers. Get ready to panic and cover the 100 million shares. Watch those shorts kill each other.
no one has this info except for SNY. They now know how successful Afrezza will be based on this slow launch, so don't be fooled by the 200 scripts per week-- it could be very bad or extremely good, depending on the number of docs having full knowledge of AFrezza.
There is a reason why market cap for mnkd was $5 billion at FDA approval. Most drugs don't get this kind of superstar status before the launch.
if only 100-300 docs have the knowledge of Afrezza and they are writting about 200 scripts each week; this translates to 1-2 scripts/doc/wk. Extrapolate that to 220,000 PCPs and 5,000 endocrinologists when the floodgate is opened, then you will have 225,000-500,000 scripts/wk. Afrezza will probably be the best selling drug of all time.
strong buy here; these short hedge funds know when to cover. I think they bought infos from management; that Dianne Plumbo may have been a snitch; they let her go.